MRT-2359 is a small molecule commercialized by Monte Rosa Therapeutics, with a leading Phase II program in Small-Cell Lung Cancer. According to Globaldata, it is involved in 1 clinical trial, which is ongoing. GlobalData uses proprietary data and analytics to provide a complete picture of MRT-2359’s valuation in its risk-adjusted NPV model (rNPV). Buy the model here.
Smarter leaders trust GlobalData
The revenue for MRT-2359 is expected to reach an annual total of $40 mn by 2037 in the US based off GlobalData’s Expiry Model. The drug’s revenue forecasts along with estimated costs are used to measure the value of an investment opportunity in that drug, otherwise known as net present value (NPV). Applying the drug’s phase transition success rate to remaining R&D costs and likelihood of approval (LoA) to sales related costs provides a risk-adjusted NPV model (rNPV). The rNPV model is a more conservative valuation measure that accounts for the risk of a drug in clinical development failing to progress.
MRT-2359 Overview
MRT-2359 is under development for the treatment of solid tumors including small-cell lung cancer, non-small cell lung cancer, diffuse large B-cell lymphoma, multiple myeloma (Kahler disease), neuroendocrine cancer including prostate cancer, bladder cancer, HER2- breast cancer. The drug candidate is a molecular glue degrader selectively targeting GSPT1. It is administered orally and is being developed based on Quantitative and Engineered Elimination of Neosubstrates (QuEEN) platform.
Monte Rosa Therapeutics Overview
Monte Rosa Therapeutics is a biotechnology company developing small molecules to degrade disease-related proteins. The company is headquartered in Boston, Massachusetts, the US.
The operating loss of the company was US$143.3 million in FY2023, compared to an operating loss of US$112.4 million in FY2022. The net loss of the company was US$135.4 million in FY2023, compared to a net loss of US$108.5 million in FY2022.
The company reported revenues of US$4.7 million for the second quarter ended June 2024, compared to a revenue of US$1.1 million the previous quarter.
For a complete picture of MRT-2359’s valuation, buy the drug’s risk-adjusted NPV model (rNPV) here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
To create this model, GlobalData takes into account factors including patent law, known and projected regulatory approval processes, cash flows, drug margins and company expenses. Combining these data points with GlobalData’s world class analysis creates high value models that companies can use to help in evaluation processes for each drug or company.
The rNPV method integrates the probability of a drug reaching a clinical stage into the cash flow at that time, which provides a more accurate valuation, as it considers the probability that the drug never makes it through the clinical pathway to commercialization. GlobalData’s rNPV model uses proprietary likelihood of approval (LoA) and phase transition success rate (PTSR) data for the indication in the highest development stage, which can be found on GlobalData’s Pharmaceutical Intelligence Center.
